We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global Molecular Diagnostics Market is Skyrocketing

By Biotechdaily staff writers
Posted on 14 Feb 2007
The US$18 billion market for both commercial and home-brew molecular diagnostics could skyrocket into a more than $92 billion market by 2016, according to a new report from medical markets research firm Kalorama Information (Rockville, MD, USA). More...


The addition of new tests in high-volume testing, coupled with the introduction of new instrumentation, which will provide greater ease, speed, and quality in performing these tests, will be primary market drivers.

Growing at an average annual rate of more than 41%, the potential for molecular diagnostics - particularly in the United States, which represents the largest actual and potential market and has the most favorable market conditions for molecular diagnostics entry and marketing - is quite phenomenal. Molecular diagnostics addressing the pharmacogenetic testing segment will make up most of market growth.

Currently the second largest market sector behind diagnostics for infectious diseases, the pharmacogenetic sector is projected to take off from its current $3 plus billion in revenues to more than $60 billion in 2016. Tests for HIV/AIDS and cancer treatments will factor heavily into this market growth.

As each molecular diagnostic moves from a specialized technology of limited use to a mainstream activity in the clinical laboratory once its relevance and role in the treatment of disease are established, the use of these tests should become more of the norm in the global market, noted Kenneth G. Krul, Ph.D., the report's author. Keeping in mind that for each new assay developed, there may be multiple clinical and non-clinical applications provides developers with greater opportunity for growth and return on their investment.




Related Links:
Kalorama Information

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.